Biotech investors wary of Warren tax proposals

Biotech investors are concerned that Sen. Elizabeth Warren’s plans for funding Medicare for All could disincentivize the long-term investments that are the industry’s lifeblood. They are especially worried about unintended consequences of a proposal to tax capital gains annually, rather than when assets are sold.

Warren (D-Mass.) wants to impose a “mark-to-market” scheme that would tax capital gains income of the top 1% of earners annually. ...